Athersys has filed for bankruptcy and secured a deal to sell off its assets to long-standing partner and regenerative medicine company Healios.
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (Healios), has provided updates on its two clinical programs evaluating MultiStem® (invimestrocel, HLCM051) cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome (ARDS) in Japan on an exclusive basis.
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has completed enrollment in its TREASURE study in Japan, evaluating MultiStem® (invimestrocel) cell therapy treatment in patients who have suffered an ischemic stroke. The details are provided in Healios’ press release: https://ssl4.eir-parts.net/doc/4593/tdnet/2013098/00.pdf